Cadrenal Therapeutics CEO Quang Pham Sells Shares
Quang Pham sold 12,996 shares of Cadrenal Therapeutics, Inc. valued at $51,204.
Key Points
- On June 12, 2026, Quang Pham sold 12,996 shares of Cadrenal Therapeutics, Inc. for $51,204.
- Shares of Cadrenal Therapeutics traded at $3.33, with a market cap of $10.3 million and a 52-week high of $14.64.
- Vanguard Capital Management increased its holdings to 45,201 shares, valued at $231,429.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Quang Pham, the Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc. (NasdaqCM: CVKD), sold 12,996 shares of the company on June 12, 2026. The shares were sold at an average price of $3.94, totaling $51,204. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Cadrenal Therapeutics, Inc.
Quang Pham has been actively trading shares of Cadrenal Therapeutics. On June 15, 2026, he sold another 3,666 shares at $3.58 each. Earlier, on June 11, 2026, he sold 1,462 shares at $4.12, and on June 10, 2026, he sold 3,500 shares at $4.21 under a pre-planned trading arrangement.
Other Institutional Activity in Cadrenal Therapeutics
Several institutional investors have also made moves in Cadrenal Therapeutics. Vanguard Capital Management LLC added 45,201 shares, bringing its total to 45,201 shares valued at approximately $231,429. Geode Capital Management, LLC increased its position by 7,098 shares, ending with 21,626 shares worth $110,724. BlackRock, Inc. grew its holdings by 1,974 shares to a total of 5,496 shares, valued at $28,140.
Cadrenal Therapeutics, Inc. Stock Up 116.2%
Shares of Cadrenal Therapeutics, Inc. recently traded at $3.33. The company has a market capitalization of about $10.3 million. The stock's 52-week range is between $3.27 and $14.64. The 50-day moving average is $5.07, and the 200-day moving average is $8.60. With a current ratio of 2.68 and a quick ratio of 2.17, the company's financial position remains stable despite its lack of profitability, reflected in a negative forward P/E ratio.
$CVKD stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On April 7, 2026, HC Wainwright & Co. maintained its 'buy' rating on Cadrenal Therapeutics with a price target of $13. The consensus among analysts is a 'buy' rating, with an average target price of $27.67 based on three analyst opinions.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc. is a biopharmaceutical company headquartered in Ponte Vedra, Florida. It focuses on developing treatments for severe immune and thrombotic conditions. The company's leading product, Tecarfarin, is in a Phase 3 trial for preventing blood clots in patients needing chronic anticoagulation. Cadrenal also works on CAD-1005 and Frunexian, targeting thrombotic disorders and acute hospital settings. Founded in 2022, the company is led by CEO Quang X. Pham.
Bottom Line
Quang Pham's recent share sales reflect his ongoing activity in the market, though not necessarily a negative signal. Cadrenal Therapeutics continues to attract institutional interest, as evidenced by recent moves by major funds. Investors keep a close eye on these developments, keeping in mind that insider transactions are reported after they occur and may not indicate future intentions.
Get Cadrenal Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CVKD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.